BioCentury
ARTICLE | Clinical News

May 21 Clinical Quick Takes: Array gains on colorectal cancer plans; plus Tocagen, Promedior

May 21, 2019 11:51 PM UTC

Array planning submissions for colorectal cancer triplet
Array BioPharma Inc. (NASDAQ:ARRY) gained $4.81 (23%) to $25.77 on Tuesday after interim data from the Phase III BEACON CRC trial to treat BRAF V600E-mutant metastatic colorectal cancer (mCRC) showed that Braftovi encorafenib plus Mektovi binimetinib and Erbitux cetuximab met the primary endpoints of improving confirmed objective response rate (26.1% vs. 1.9%, p<0.0001) and median overall survival (9 vs. 5.4 months, HR=0.52, 95% CI: 0.39, 0.7, p<0.0001) vs. Erbitux plus an irinotecan-based therapy. The company plans to submit the data for marketing approval next half.

Tocagen down on glioma immunotherapy update
Shares of Tocagen Inc. (NASDAQ:TOCA) were off $2.53 (29%) to $6.29 in after-hours trading Tuesday after the company said the Phase III Toca 5 trial of its immunotherapy comprising vocimagene amiretrorepvec/extended-release 5-fluorocytosine (Toca 511/Toca FC) to treat recurrent high-grade glioma will continue without modification following a planned interim analysis by an IDMC. Investors may have been hoping to see a positive readout at the interim look; but CEO Marty Duvall said the company believes the longer-term follow-up of patients in the final analysis will be important in assessing both primary and secondary endpoints. The trial's primary endpoint is overall survival and a final analysis is due to report by year end...